InvestorsHub Logo
Followers 2
Posts 503
Boards Moderated 0
Alias Born 07/15/2007

Re: JONAH 2 post# 1992

Tuesday, 02/15/2011 1:16:08 PM

Tuesday, February 15, 2011 1:16:08 PM

Post# of 8169
And whats this mean anyone ??

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


SCHEDULE 13G


UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. ___)


NOVELOS THERAPEUTICS, INC.

--------------------------------------------------------------------------------

(Name of Issuer)


COMMON STOCK, $0.00001 PAR VALUE PER SHARE
--------------------------------------------------------------------------------

(Title of Class of Securities)


67000M100
--------------------------------------------------------------------------------

(CUSIP Number)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1(b)


*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.


The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



(Continued on following page(s)



--------------------------------------------------------------------------------





CUSIP No. 67000M100 13G Page 2 of 4 Pages



1. NAMES OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON


Longview Fund L.P.
--------------------------------------------------------------------------------

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a) ¨
(b) ¨
--------------------------------------------------------------------------------

3. SEC USE ONLY


--------------------------------------------------------------------------------

4. CITIZENSHIP OR PLACE OF ORGANIZATION


California
--------------------------------------------------------------------------------

5. SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON – 44,413,360 Shares



--------------------------------------------------------------------------------
6. SHARED VOTING POWER - None



--------------------------------------------------------------------------------
7. SOLE DISPOSITIVE POWER – 44,413,360 Shares



--------------------------------------------------------------------------------
8. SHARED DISPOSITIVE POWER - None

--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON –
44,413,360 Shares



--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES o


--------------------------------------------------------------------------------

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9


8.63%
--------------------------------------------------------------------------------

12. TYPE OF REPORTING PERSON


OO



--------------------------------------------------------------------------------





CUSIP No. 67000M100 13G Page 3 of 4 Pages


ITEM 1 (a) NAME OF ISSUER: Novelos Therapeutics, Inc.


ITEM 1 (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:


One Gateway Center, Suite 504, Newton, Massachusetts 02458


ITEM 2 (a) NAME OF PERSON FILING: Longview Fund L.P.


ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:


505 Sansome Street, Suite 1275, San Francisco, CA 94111


ITEM 2 (c) CITIZENSHIP: California


ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $0.00001 par value


ITEM 2 (e) CUSIP NUMBER: 67000M100


ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR
13D-2(B): Not applicable


ITEM 4 OWNERSHIP


(a) AMOUNT BENEFICIALLY OWNED: 44,413,360 Shares


(b) PERCENT OF CLASS: 8.63%


(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:


(i) SOLE POWER TO VOTE OR DIRECT THE VOTE


44,413,360 Shares


(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE


0 Shares


(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF


44,413,360 Shares


(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF


0 Shares




--------------------------------------------------------------------------------



CUSIP No. 67000M100 13G Page 4 of 4 Pages


ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS


Not applicable


ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON


Not applicable


ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY


Not applicable


ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP


Not applicable


ITEM 9 NOTICE OF DISSOLUTION OF GROUP


Not applicable


SIGNATURE


After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


February 14, 2011
(Date)

/s/ S. Michael Rudolph
(Signature)

S. Michael Rudolph, CFO of Viking Asset
Management LLC, as Investment Manager
(Name/Title)


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CLRB News